Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
| العنوان: | Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer |
|---|---|
| المؤلفون: | Atsushi Horiike, Noriko Yanagitani, Takahiro Yoshizawa, Shingo Nishikawa, Ryo Ariyasu, Junji Koyama, Ken Uchibori, Tomoaki Sonoda, Makoto Nishio, Hironori Ninomiya, Yosuke Dotsu, Masafumi Saiki, Yuichi Ishikawa, Satoru Kitazono |
| المصدر: | Journal of Thoracic Disease. 11:1919-1928 |
| بيانات النشر: | AME Publishing Company, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, Oncology, endocrine system, medicine.medical_specialty, business.industry, Thyroid Transcription Factor 1, Thyroid, non-small cell lung cancer (NSCLC), Pembrolizumab, Odds ratio, respiratory system, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Internal medicine, medicine, Original Article, Nivolumab, business, Lung cancer, 030215 immunology, Hormone |
| الوصف: | Background: Recent studies have suggested a correlation between immune-related thyroid dysfunction (irTD) and the superior efficacy of anti-programmed cell death protein-1 (anti-PD-1) treatment in non-small cell lung cancer (NSCLC). Embryologically, the lung and thyroid are similar in origin, and thyroid transcription factor-1 (TTF-1) expresses in both organs, including NSCLC. We explored our hypothesis that TTF-1 expression in NSCLC might correlate with irTD incidence and anti-PD-1 treatment efficacy. Methods: We identified 132 patients with NSCLC treated with anti-PD-1 antibody at our hospital between December 2015 and June 2017. We evaluated TTF-1 expression in tumor by immunohistochemistry using a mouse monoclonal antibody (clone 8G7G3/1, 1:100, Dako). IrTD was defined as two or more successive abnormal levels of thyroid-stimulating hormone (TSH) during anti-PD-1 treatment. We retrospectively assessed correlations between TTF-1 expression in tumor, irTD incidence, and anti-PD-1 treatment efficacy. Results: Of 132 patients, 67 (51%) and 65 (49%) were positive and negative for TTF-1, respectively. We observed irTD in 19 patients (6 positives and 13 negatives for TTF-1). The incidence of irTD was 9% and 20% in TTF-1-positive and TTF-1-negative NSCLCs, respectively (P=0.086). Particularly, in non-squamous (NSQ) cell carcinomas, the irTD incidence was significantly higher in patients negative for TTF-1 (30%) than in those positive for TTF-1 (9%; P=0.010), and TTF-1 expression was identified as a significant risk factor for irTD on multivariate logistic regression analysis [odds ratio (OR), 0.18; 95% confidence interval (CI), 0.05–0.59; P=0.005]. Furthermore, longer median progression-free survival (10.3 months) was observed in patients with TTF-1-negative NSCLC with irTD compared to those with TTF-1-positive NSCLC with irTD, TTF-1-positive NSCLC without irTD, and TTF-1-negative NSCLC without irTD (4.2, 1.4, and 2.4 months, respectively). Conclusions: TTF-1 expression in NSCLC might correlate with irTD and anti-PD-1 treatment efficacy. |
| تدمد: | 2077-6624 2072-1439 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd1ce2a8bb1c0340835f56148a7dcd60Test https://doi.org/10.21037/jtd.2019.04.102Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fd1ce2a8bb1c0340835f56148a7dcd60 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20776624 20721439 |
|---|